Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1
Authors
Keywords
-
Journal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-25
DOI
10.1007/s10928-020-09702-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
- (2019) Francis W. Hunter et al. BRITISH JOURNAL OF CANCER
- Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach
- (2018) Alison Betts et al. mAbs
- Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
- (2018) Guangmin Li et al. MOLECULAR CANCER THERAPEUTICS
- Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
- (2018) Funda Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
- (2017) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
- (2016) Alison M. Betts et al. AAPS Journal
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
- (2014) Brendan Bender et al. AAPS Journal
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications
- (2014) Andreas Maderna et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer mouse models: Past, present and future
- (2014) Walid T. Khaled et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential
- (2014) Parvin F. Peddi et al. Therapeutic Advances in Medical Oncology
- Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery
- (2013) Bruce A. Ruggeri et al. BIOCHEMICAL PHARMACOLOGY
- Systems Pharmacology for Drug Discovery and Development: Paradigm Shift or Flash in the Pan?
- (2013) P Vicini et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach
- (2013) Nahor Haddish-Berhane et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin
- (2012) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- High Affinity Antigen Recognition of the Dual Specific Variants of Herceptin Is Entropy-Driven in Spite of Structural Plasticity
- (2011) Jenny Bostrom et al. PLoS One
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
- (2010) Nelson L. Jumbe et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
- (2009) E. A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review
- (2009) Shaheenah Dawood et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum HER-2/neuand relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
- (2008) Suhail M. Ali et al. CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search